Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment.
Purpose: Dolutegravir (DTG), an unboosted HIV integrase inhibitor (INI), is metabolized by UGT1A1 and to a minor extent by CYP3A. Renal elimination of unchanged DTG is very low (< 1 %). As renal impairment may affect pharmacokinetics (PK), even for drugs primarily metabolized or secreted in bile, th...
| Publicado en: | European Journal of Clinical Pharmacology Vol. 70; no. 1; pp. 29 - 36 |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Springer Nature
Jan2014
|
| Acceso en línea: | Ver este registro en EBSCOhost |